UNIVERSITY OF OXFORD, Oxford, United Kingdom Read more
Prof. Stuart CONWAY
Stuart Conway is a Professor of Organic Chemistry at the University of Oxford, and the E. P. Abraham Cephalosporin Fellow in Organic Chemistry at St Hugh's College, Oxford. He studied Chemistry with Medicinal Chemistry at the University of Warwick before undertaking PhD studies with Professor David Jane and Professor Jeff Watkins FRS at the University of Bristol. Stuart completed post-doctoral studies with Professor Andrew Holmes FRS at the University of Cambridge. In 2003, he was appointed as a Lecturer in Bioorganic Chemistry at the University of St Andrews, in 2008 was appointed as an Associate Professor at Oxford, and in October 2014 he was promoted to Full Professor. Between March and August 2013 Stuart was a Visiting Associate at the California Institute of Technology. Since 2016 he has been an Associate Editor for the Journal of Medicinal Chemistry and he is the President-elect of the RSC Organic Division. His research focuses on the development of chemical tools to study biological systems.
The Emergence of Antibody-Drug Conjugates (ADCs) as Targeted Cancer Therapies: From Ehrlich's "Magic Bullet" Concept to Calicheamicin γ1I and Mylotarg
K. C. Nicolaou is currently the Harry C. Olga K. Wiess Professor of Chemistry at Rice University. He previously served concurrently as the founding chairman of the Chemistry Department at the Scripps Research Institute, a distinguished Professor of Chemistry at the University of California, San Diego (1989-2013), and the founding Director of the Chemical Synthesis Laboratory at ICES, A*STAR at Biopolis, Singapore. His research activities focus on the discovery and development of new synthetic strategies and technologies, and their applications to the total synthesis of natural and designed molecules of biological and medical importance. He is a co-author of the Classics in Total Synthesis series (I, II, III) and Molecules that Changed the World.
Title to be announced
Dr Cornelia ZUMBRUNN
IDORSIA PHARMACEUTICALS, Allschwil, Switzerland Read more
Dr Cornelia ZUMBRUNN
Cornelia Zumbrunn holds a position as Principal Scientist (medicinal chemist and project leader) in the field of antibacterial research and cardiovascular diseases. Since 2004 she worked in the research department of Actelion Pharmaceuticals Ltd, now Idorsia Pharmaceuticals Ltd. (Allschwil, Switzerland). Previous positions include Morphochem AG and Hoffmann-LaRoche, after a postdoc at Cambridge University (UK). Cornelia obtained her PhD from Hoffmann-LaRoche and the University of Zürich after having completed studies in organic chemistry in Fribourg (CH) and Neuchâtel (CH). Her research focused on the discovery of antibiotics with novel modes of action and other projects in the areas of central nervous systems and cardiovascular research. She is a board member and the secretary of the Division of Medicinal Chemistry and Chemical Biology of the Swiss Chemical Society (DMCCB).